The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high ...

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target following ...

BTIG analysts have downgraded (NYSE:GMED) from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

Globus Medical (NYSE:GMED) announced that its board of directors authorized a share repurchase program totaling up to $500 ...

The United States market has experienced a positive trend, rising 2.9% over the last week and 12% over the past year, with earnings projected to grow by 14% annually in the coming years. In this ...

Thornal will join the orthopedics company as group president for global businesses and the Americas, a newly created position ...

Chester County Futures (CCF), in collaboration with Globus Medical, recently provided a transformative learning experience ...

From new partnerships and launches, here are six developments from Globus Medical so far in 2025. 1. OsteoCentric Technologies entered into a non-exclusive licensing agreement with Globus Medical.

Globus Medical, Inc.’s GMED share price has dipped by 21.03%, which has investors questioning if this is right time to buy.

Globus Medical expects full-year earnings in the range of $3 to $3.30 per share, with revenue in the range of $2.8 billion to $2.9 billion. This story was generated by Automated Insights ( ...

Stay well-informed and make prudent decisions using our Ratings Table. Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals ...